Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;67(6):2067-2073.
doi: 10.1007/s10620-021-07040-z. Epub 2021 May 12.

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey

Bénédicte Caron  1 , Elise Neuville  1 , Laurent Peyrin-Biroulet  2
Affiliations

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey

Bénédicte Caron et al. Dig Dis Sci. 2022 Jun.

Abstract

Background: Vaccination against COVID-19 is a major public health challenge, including the community of patients with inflammatory bowel disease. Vaccination coverage is suboptimal in inflammatory bowel disease population. It is of paramount importance to ensure an effective and rapid vaccination program with the adherence of the largest number of well-informed patients.

Aims: We assessed the acceptance of COVID-19 vaccination among inflammatory bowel disease patients.

Methods: We performed a survey as part of routine practice, between January 8th and February 22nd, 2021. All consecutive adult patients followed at Nancy University Hospital for inflammatory bowel disease were included. Patients completed a self-administered, structured, paper-based questionnaire. Demographic data, medical history, knowledge, and perceptions of COVID-19 vaccination were collected.

Results: Among the 104 patients who responded to the survey, 57 patients (54.8%) had intent to receive the COVID-19 vaccine. Vaccine efficacy, social responsibility, herd immunity, and desire to return to normal life were associated with self-reported willingness to receive a vaccine (20.2%, 20.2%, 11.5%, and 15.4%, respectively). Unknown long-term safety, risk of adverse reaction to vaccine and concern that the vaccine is being developed too quickly were the most commonly reported reasons for non-uptake (27.9%, 15.4%, and 12.5%, respectively).

Conclusion: Half of the patients with inflammatory bowel disease would like to be vaccinated against SARS-CoV-2. This rate is similar to that reported in the French general population. Despite some concerns, patients with inflammatory bowel disease understood the necessity to be vaccinated against COVID-19.

Keywords: COVID-19; Inflammatory bowel disease; SARS-CoV-2; Vaccination.

PubMed Disclaimer

Conflict of interest statement

B Caron and E Neuville declare no conflict of interest. L Peyrin-Biroulet has served as a speaker, consultant, and advisory board member for Merck, Abbvie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Hospira/Pfizer, Celltrion, Takeda, Biogaran, Boerhinger-Ingelheim, Lilly, HAC- Pharma, Index Pharmaceuticals, Amgen, Sandoz, For- ward Pharma GmbH, Celgene, Biogen, Lycera, Samsung Bioepis, Theravance.

Figures

Fig. 1
Fig. 1
COVID-19 vaccination intent among patients with inflammatory bowel disease
See this image and copyright information in PMC

Comment in

References

    1. Allocca M, Chaparro M, Gonzalez HA, et al. Patients with inflammatory bowel disease are not at increased risk of COVID-19: a large multinational cohort study. J Clin Med. 2020;9:3533. doi: 10.3390/jcm9113533. - DOI - PMC - PubMed
    1. Magro F, Rahier J-F, Abreu C, et al. Inflammatory bowel disease management during the COVID-19 outbreak: the ten do’s and don’ts from the ECCO-COVID taskforce. J Crohns Colitis. 2020;14:S798–S806. doi: 10.1093/ecco-jcc/jjaa160. - DOI - PMC - PubMed
    1. Allocca M, Fiorino G, Zallot C, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol. 2020;18:2134–2135. doi: 10.1016/j.cgh.2020.04.071. - DOI - PMC - PubMed
    1. Papa A, Gasbarrini A, Lopetuso LR. Winter is coming and COVID-19 vaccine is available! The role of gastroenterologist in increasing COVID-19 vaccine acceptability among IBD patients. Gastroenterology. 2021 doi: 10.1053/j.gastro.2020.12.066. - DOI - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed

Substances